Edgewise Therapeutics, Inc. (EWTX) Net income 2020–2025
Edgewise Therapeutics, Inc. (EWTX) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$167.8MFY2025 · since FY2020: -$17.1M → -$167.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$167.8M | -25.4% |
| FY2024 | -$133.8M | -33.6% |
| FY2023 | -$100.2M | -48.1% |
| FY2022 | -$67.6M | -58.0% |
| FY2021 | -$42.8M | -150.0% |
| FY2020 | -$17.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More EWTX financial trends
EWTX RevenueEWTX Net marginEWTX Gross profitEWTX Gross marginEWTX Operating incomeEWTX Operating marginEWTX Operating cash flowEWTX Free cash flowEWTX Capital expendituresEWTX Return on equityEWTX Stock buybacksEWTX Dividends paidEWTX Total assetsEWTX Total liabilitiesEWTX Shareholders’ equityEWTX overview →